--- title: "Weekly Recap | ImmunityBio +7.21%, a high-volume week" type: "News" locale: "en" url: "https://longbridge.com/en/news/299511752.md" description: "ImmunityBio ended the week at $8.48, up 7.21%, while the S&P 500 slipped 0.08%, leaving the stock ahead of the benchmark by roughly 7.29 percentage points. Monday opened strong at $8.37, but the stock faded over Tuesday and Wednesday to $7.91. Thursday brought a sharp rally on 19.2m shares traded, with the intraday peak at $8.80. Friday settled close to the week’s high at $8.48. Weekly amplitude was 13." datetime: "2026-09-19T06:10:34.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/299511752.md) - [en](https://longbridge.com/en/news/299511752.md) - [zh-HK](https://longbridge.com/zh-HK/news/299511752.md) generator: "portal-rs" --- # Weekly Recap | ImmunityBio +7.21%, a high-volume week ## The Week ImmunityBio ended the week at $8.48, up 7.21%, while the S&P 500 slipped 0.08%, leaving the stock ahead of the benchmark by roughly 7.29 percentage points. Monday opened strong at $8.37, but the stock faded over Tuesday and Wednesday to $7.91. Thursday brought a sharp rally on 19.2m shares traded, with the intraday peak at $8.80. Friday settled close to the week’s high at $8.48. Weekly amplitude was 13.18%, and average daily volume ran about 44% above its recent median, marking one of the more active stretches in the past 60 sessions. ## Key Events There were no company-specific product or earnings announcements this week. On Tuesday, a cluster of US market commentary mentioned ImmunityBio among high-growth companies favoured by insiders, placing it within broader biotech and edge-asset narratives. In the same window, English-language coverage noted that Patrick Soon-Shiong, who has ties to ImmunityBio’s founder background, joined the board of PDS Biotech. That event belongs to a different issuer, not ImmunityBio itself. Overall, the week’s news flow leaned toward sector sentiment rather than new company-level facts, with the price and volume move showing up mostly as market behaviour. ## Analyst Ratings Four brokers cover the name: three rate it buy and one overweight, with no holds, underweights or sells. The consensus recommendation is strong buy, and the consensus target price is $12.75, implying roughly 50.35% above the latest close of $8.48. Target prices range from $12 to $15, suggesting limited disagreement. Within the biotech industry, its rating rank sits at 309 out of 501 companies. ## The Week Ahead No corporate earnings are scheduled for ImmunityBio in the coming week. On the macro calendar, the Richmond Fed composite index arrives on Tuesday, followed by initial jobless claims and new home sales on Thursday, plus weekly EIA crude and natural gas inventory data midweek. Sentiment in biotech could remain tied to macro liquidity and risk appetite. Whether this week’s volume expansion carries into next week depends on how the market opens next Monday. ## In Short ImmunityBio gained 7.21% for the week on no fresh company-specific news, outperforming the S&P 500 with a notable expansion in volume. The analyst backdrop is constructive, with a strong-buy consensus and a target price roughly half above spot. On the funding side, the latest trading day showed large, medium and small orders nearly balanced, with no clear single-sided net flow. Earnings per share and book value per share are both negative, so conventional P/E and P/B metrics do not apply. The question now is whether next week’s macro data and sector mood can sustain the rally. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [IBRX.US](https://longbridge.com/en/quote/IBRX.US.md) ## Related News & Research - [Is ImmunityBio (IBRX) A Bargain As Turkey Expansion Fuels Fresh Growth Hopes?](https://longbridge.com/en/news/300119345.md) - [Does ImmunityBio’s (IBRX) Jim Yong Kim Hire Transform Its Global Access Strategy For Immunotherapies?](https://longbridge.com/en/news/296830934.md) - [AI Security Push Might Change The Case For Okta Stock](https://longbridge.com/en/news/300209980.md) - [Amazon.com, Inc. $AMZN Shares Newly Bought by Glenview Trust Co](https://longbridge.com/en/news/300214023.md) - [Big AI's content problem: Take the work, keep the money](https://longbridge.com/en/news/300217405.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**